05/04/2004
New Method for Purification of ReGen Therapeutics’ potential Alzheimer’s Therapy published
ReGen Therapeutics Plc (‘ReGen’), announces that a paper has recently been published* by Professor Marian Kruzel (consultant to ReGen) summarising the principles of a new method for the extraction from colostrum of ColostrininTM, ReGen’s potential therapy for Alzheimer’s disease.
Percy Lomax ReGen’s Executive Chairman said, ‘As this publication summarises, we now have a new process for the extraction of Colostrinin™ from colostrum which we believe will be more cost-effective and appropriate to industrial scale production than the original benchscale method. As we have reported previously, this new method is now being scaled up under a contract with a USA-based bovine colostrum processor. Having a good manufacturing process is very important in being able to attract a licensing partner’.
*Kruzel M L et al, The Protein Journal, 23/2 (February 2004)
Professor Marian Kruzel PhD – Scientific Consultant to ReGen Professor Marian Kruzel is a faculty member of the Department of Integrative Biology and Pharmacology, the University of Texas, Medical School at Houston. He is an internationally recognized immunologist with an established interest and expertise in inflammation and age-related pathophysiology. He is the recipient of numerous grants and a participant in NIH funded projects. Also, he serves as a reviewer on several scientific journals, including Clinical and Experimental Immunology, Cellular and Molecular Biology Letters, and Journal of Experimental Therapeutics and Oncology. In 1999 Prof. Kruzel founded PharmaReview Corporation, a consulting firm that provides guidance to bio-medical research companies in various project design and development of clinical protocols. He is the former chairman of the board of Cancer Coalition of America.
Through a consultancy agreement with the company Prof. Kruzel is responsible to the Board for scientific research and development and management of the scientific aspects of future clinical development on behalf of the company.
Further information:
Andrew Marshall
Marshall Robinson Roe
Tel: 020 7960 6007